Prognostic Significance of Platelet-to-Lymphocyte Ratio (PLR) in Extrahepatic Metastasis of Hepatocellular Carcinoma After Curative Resection

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Sasaki A, Kai S, Endo Y, et al. Hepatitis B virus infection predicts extrahepatic metastasis after hepatic resection in patients with large hepatocellular carcinoma. Ann Surg Oncol. 2007;14(11):3181–3187. PMID: 17846843. doi:10.1245/s10434-007-9570-x17846843
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Matsuo K, Takeda K, Nagano Y, Togo S. Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection. World J Surg. 2008;32(8):1738–1747. PMID: 18463920. doi:10.1007/s00268-008-9613-x18463920
   PubMed Web of Science ®Google Scholar
• Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg. 2012;36(1):136–143. PMID: 22051887. doi:10.1007/s00268-011-1317-y22051887
   PubMed Web of Science ®Google Scholar
• Byeon J, Cho EH, Kim SB, Choi DW. Extrahepatic recurrence of hepatocellular carcinoma after curative hepatic resection. Korean J Hepatobiliary Pancreat Surg. 2012;16(3):93–97. PMID: 26388915; PMCID: PMC4575006. doi:10.14701/kjhbps.2012.16.3.9326388915
   PubMedGoogle Scholar
• Wang L, Ye G, Zhan C, et al. Clinical factors predictive of a better prognosis of pulmonary metastasectomy for hepatocellular carcinoma. Ann Thorac Surg. 2019;108(6):1685–1691. PMID: 31445050. doi:10.1016/j.athoracsur.2019.06.08631445050
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. PMID: 18650514. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. PMID: 29433850. doi:10.1016/S0140-6736(18)30207-129433850
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang J, Wang P. The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: a meta-analysis of observational studies. PLoS One. 2018;13(10):e0202987 PMID: 30312295; PMCID: PMC6185720. doi:10.1371/journal.pone.020298730312295
   PubMed Web of Science ®Google Scholar
• Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015;10(3):e0119312 PMID: 25742141; PMCID: PMC4351002. doi:10.1371/journal.pone.011931225742141
   PubMed Web of Science ®Google Scholar
• Li M, Zhao Y, Liu X, Zhang S, Jiang Y, Yang Z. Early risk warning system for distant metastasis of hepatitis B virus-associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett. 2020;19(4):3249–3257. PMID: 32256820; PMCID: PMC7074481. doi:10.3892/ol.2020.1142332256820
   PubMed Web of Science ®Google Scholar
• Ha Y, Mohamed Ali MA, Petersen MM, et al. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int. 2020;14(5):776–787. PMID: 32740886. doi:10.1007/s12072-020-10076-432740886
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu Z, Zhao X, Mao Z, Bai L. A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients. Artif Cells Nanomed Biotechnol. 2019;47(1):2246–2255. PMID: 31169437. doi:10.1080/21691401.2019.157317431169437
   PubMed Web of Science ®Google Scholar
• Li J, Liao Y, Suo L, et al. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):9229 PMID: 28835713; PMCID: PMC5569032. doi:10.1038/s41598-017-09696-y28835713
   PubMed Web of Science ®Google Scholar
• Jin C, Li C, Peng W, et al. Changes of platelet times neutrophil to lymphocyte ratio predict BCLC stage A hepatocellular carcinoma survival. Medicine. 2017;96(33):e7821 PMID: 28816981; PMCID: PMC5571718. doi:10.1097/MD.000000000000782128816981
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. PMID: 21376230. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706. PMID: 22224761. doi:10.1146/annurev-immunol-020711-07500822224761
   PubMed Web of Science ®Google Scholar
• Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma”. Review article. Ann Hepatol. 2020;22:S1665-2681(20)30164-2 PMID: 32896610. doi:10.1016/j.aohep.2020.08.067
   PubMed Web of Science ®Google Scholar
• Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202. PMID: 17263976. doi:10.1016/j.surg.2006.06.03317263976
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.29628281
   PubMed Web of Science ®Google Scholar
• Chun YS, Pawlik TM, Vauthey J-N. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845–847. doi:10.1245/s10434-017-6025-x28752469
   PubMed Web of Science ®Google Scholar
• Li J, Liu Y, Yan Z, et al. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer. 2014;110(5):1110–1117. PMID: 24481404; PMCID: PMC3950869. doi:10.1038/bjc.2014.1924481404
   PubMed Web of Science ®Google Scholar
• He C, Peng W, Liu X, Li C, Li X, Wen TF. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: a meta-analysis. Medicine. 2019;98(31):e16557 PMID: 31374020; PMCID: PMC6709300. doi:10.1097/MD.000000000001655731374020
   PubMed Web of Science ®Google Scholar
• Bihari C, Rastogi A, Shasthry SM, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS. 2016;124(9):776–786. PMID: 27457354. doi:10.1111/apm.1257427457354
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010;52(3):370–379. PMID: 19720422. doi:10.1016/j.jhep.2009.07.01319720422
   PubMed Web of Science ®Google Scholar
• Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396–407. PMID: 24751830. doi:10.1016/j.jhep.2014.04.01224751830
   PubMed Web of Science ®Google Scholar
• Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–1284. PMID: 26192220. doi:10.1016/j.jhep.2015.07.00426192220
   PubMed Web of Science ®Google Scholar